Australia markets open in 2 hours 40 minutes
  • ALL ORDS

    6,373.70
    -10.00 (-0.16%)
     
  • AUD/USD

    0.7142
    +0.0025 (+0.35%)
     
  • ASX 200

    6,167.00
    -6.80 (-0.11%)
     
  • OIL

    39.78
    -0.07 (-0.18%)
     
  • GOLD

    1,903.40
    -1.80 (-0.09%)
     
  • BTC-AUD

    18,297.44
    +63.05 (+0.35%)
     
  • CMC Crypto 200

    260.05
    -1.40 (-0.54%)
     

If You Had Bought MacroGenics (NASDAQ:MGNX) Stock A Year Ago, You Could Pocket A 120% Gain Today

Simply Wall St
·3-min read

The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But if you pick the right stock, you can make a lot more than 100%. Take, for example MacroGenics, Inc. (NASDAQ:MGNX). Its share price is already up an impressive 120% in the last twelve months. In the last week the share price is up 4.7%. And shareholders have also done well over the long term, with an increase of 64% in the last three years.

Check out our latest analysis for MacroGenics

Because MacroGenics made a loss in the last twelve months, we think the market is probably more focussed on revenue and revenue growth, at least for now. Shareholders of unprofitable companies usually expect strong revenue growth. That's because it's hard to be confident a company will be sustainable if revenue growth is negligible, and it never makes a profit.

MacroGenics grew its revenue by 37% last year. We respect that sort of growth, no doubt. The revenue growth is decent but the share price had an even better year, gaining 120%. Given that the business has made good progress on the top line, it would be worth taking a look at its path to profitability. But investors need to be wary of how the 'fear of missing out' could influence them to buy without doing thorough research.

The graphic below depicts how earnings and revenue have changed over time (unveil the exact values by clicking on the image).

earnings-and-revenue-growth
earnings-and-revenue-growth

You can see how its balance sheet has strengthened (or weakened) over time in this free interactive graphic.

A Different Perspective

It's good to see that MacroGenics has rewarded shareholders with a total shareholder return of 120% in the last twelve months. Since the one-year TSR is better than the five-year TSR (the latter coming in at 1.4% per year), it would seem that the stock's performance has improved in recent times. Given the share price momentum remains strong, it might be worth taking a closer look at the stock, lest you miss an opportunity. It's always interesting to track share price performance over the longer term. But to understand MacroGenics better, we need to consider many other factors. For example, we've discovered 3 warning signs for MacroGenics that you should be aware of before investing here.

If you would prefer to check out another company -- one with potentially superior financials -- then do not miss this free list of companies that have proven they can grow earnings.

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on US exchanges.

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com.